Logo image of ALBPS.PA

BIOPHYTIS (ALBPS.PA) Stock Fundamental Analysis

EPA:ALBPS - Euronext Paris - Matif - FR001400OLP5 - Common Stock - Currency: EUR

0.1806  -0.01 (-6.91%)

Fundamental Rating

0

Overall ALBPS gets a fundamental rating of 0 out of 10. We evaluated ALBPS against 73 industry peers in the Biotechnology industry. Both the profitability and financial health of ALBPS have multiple concerns. ALBPS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALBPS had negative earnings in the past year.
ALBPS had a negative operating cash flow in the past year.
In the past 5 years ALBPS always reported negative net income.
ALBPS had a negative operating cash flow in each of the past 5 years.
ALBPS.PA Yearly Net Income VS EBIT VS OCF VS FCFALBPS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

ALBPS has a Return On Assets of -172.99%. This is amonst the worse of the industry: ALBPS underperforms 83.56% of its industry peers.
Industry RankSector Rank
ROA -172.99%
ROE N/A
ROIC N/A
ROA(3y)-113.95%
ROA(5y)-107.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALBPS.PA Yearly ROA, ROE, ROICALBPS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K -1K 2K

1.3 Margins

ALBPS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALBPS.PA Yearly Profit, Operating, Gross MarginsALBPS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for ALBPS has been increased compared to 1 year ago.
The number of shares outstanding for ALBPS has been reduced compared to 5 years ago.
The debt/assets ratio for ALBPS is higher compared to a year ago.
ALBPS.PA Yearly Shares OutstandingALBPS.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
ALBPS.PA Yearly Total Debt VS Total AssetsALBPS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -9.64, we must say that ALBPS is in the distress zone and has some risk of bankruptcy.
ALBPS's Altman-Z score of -9.64 is on the low side compared to the rest of the industry. ALBPS is outperformed by 76.71% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.64
ROIC/WACCN/A
WACCN/A
ALBPS.PA Yearly LT Debt VS Equity VS FCFALBPS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

2.3 Liquidity

ALBPS has a Current Ratio of 0.41. This is a bad value and indicates that ALBPS is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.41, ALBPS is not doing good in the industry: 84.93% of the companies in the same industry are doing better.
ALBPS has a Quick Ratio of 0.41. This is a bad value and indicates that ALBPS is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.41, ALBPS is doing worse than 82.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.41
Quick Ratio 0.41
ALBPS.PA Yearly Current Assets VS Current LiabilitesALBPS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ALBPS have decreased strongly by -8080.37% in the last year.
EPS 1Y (TTM)-8080.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8203%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 23.35% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y65.17%
EPS Next 2Y31.34%
EPS Next 3Y23.35%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALBPS.PA Yearly Revenue VS EstimatesALBPS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2024 2025 2026 10M 20M 30M 40M
ALBPS.PA Yearly EPS VS EstimatesALBPS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -100 -200 -300 -400

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALBPS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALBPS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALBPS.PA Price Earnings VS Forward Price EarningsALBPS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALBPS.PA Per share dataALBPS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as ALBPS's earnings are expected to grow with 23.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.34%
EPS Next 3Y23.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALBPS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOPHYTIS

EPA:ALBPS (8/6/2025, 7:00:00 PM)

0.1806

-0.01 (-6.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-07 2025-04-07/amc
Earnings (Next)09-29 2025-09-29
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.22%
Ins Owner ChangeN/A
Market Cap2.07M
Analysts84.44
Price Target0.79 (337.43%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.54
EYN/A
EPS(NY)-1.7
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.93
OCFYN/A
SpS0
BVpS-0.56
TBVpS-0.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -172.99%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-113.95%
ROA(5y)-107.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.12%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.41
Quick Ratio 0.41
Altman-Z -9.64
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)55.71%
Cap/Depr(5y)70.24%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8080.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8203%
EPS Next Y65.17%
EPS Next 2Y31.34%
EPS Next 3Y23.35%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y31.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.7%
EBIT Next 3Y33.61%
EBIT Next 5YN/A
FCF growth 1Y48.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.16%
OCF growth 3YN/A
OCF growth 5YN/A